MA33761B1 - Dispersion solide de rifaximine - Google Patents

Dispersion solide de rifaximine

Info

Publication number
MA33761B1
MA33761B1 MA34885A MA34885A MA33761B1 MA 33761 B1 MA33761 B1 MA 33761B1 MA 34885 A MA34885 A MA 34885A MA 34885 A MA34885 A MA 34885A MA 33761 B1 MA33761 B1 MA 33761B1
Authority
MA
Morocco
Prior art keywords
solid dispersion
reximine
rifaximin
relates
pharmaceutically acceptable
Prior art date
Application number
MA34885A
Other languages
Arabic (ar)
English (en)
Inventor
Shirishkumar Kulkarni
Satish Kumar Dalal
Harshal Anil Jahagirdar
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33761(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA33761B1 publication Critical patent/MA33761B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une dispersion solide de rifaximine comprenant de la rifaximine et un véhicule pharmaceutiquement acceptable. L'invention concerne également une composition pharmaceutique comprenant la dispersion solide de rifaximine.
MA34885A 2009-10-27 2012-05-22 Dispersion solide de rifaximine MA33761B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1287KO2009 2009-10-27
PCT/IN2010/000694 WO2011051971A2 (fr) 2009-10-27 2010-10-27 Dispersion solide de rifaximine

Publications (1)

Publication Number Publication Date
MA33761B1 true MA33761B1 (fr) 2012-11-01

Family

ID=43922730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34885A MA33761B1 (fr) 2009-10-27 2012-05-22 Dispersion solide de rifaximine

Country Status (22)

Country Link
US (3) US20120214833A1 (fr)
EP (1) EP2493456B1 (fr)
JP (2) JP6211768B2 (fr)
KR (5) KR20140015140A (fr)
CN (2) CN113274355B (fr)
AU (2) AU2010313078A1 (fr)
CA (1) CA2778981C (fr)
CL (1) CL2012001080A1 (fr)
ES (1) ES2712080T3 (fr)
GE (1) GEP201706693B (fr)
IL (1) IL219508A (fr)
MA (1) MA33761B1 (fr)
MX (1) MX346660B (fr)
MY (1) MY177151A (fr)
NZ (1) NZ599944A (fr)
PE (1) PE20121185A1 (fr)
RU (1) RU2012121599A (fr)
SG (1) SG10201501054TA (fr)
TN (1) TN2012000195A1 (fr)
UA (1) UA110199C2 (fr)
WO (1) WO2011051971A2 (fr)
ZA (1) ZA201203226B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG10201607926VA (en) 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
NZ599944A (en) * 2009-10-27 2015-10-30 Lupin Ltd Solid dispersion of rifaximin
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
AU2010339573B2 (en) 2009-12-31 2014-08-28 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ES2801678T3 (es) * 2010-07-12 2021-01-12 Salix Pharmaceuticals Inc Formulaciones de rifaximina y sus usos
US8735419B2 (en) 2011-02-11 2014-05-27 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
WO2013112809A2 (fr) * 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd Dérivé de rifaximine et ses utilisations
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014013498A1 (fr) * 2012-07-17 2014-01-23 Symed Labs Limited Coprécipités amorphes de linézolide
US20160206564A1 (en) * 2013-09-27 2016-07-21 Ira Milton Trachtman Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
WO2015173697A1 (fr) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. Nouvelle forme cristalline solvatée de la rifaximine, production, compositions et utilisations associées
EP3518924B1 (fr) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Formes de dispersions solides de rifaximine
CN106491558A (zh) * 2016-12-09 2017-03-15 福建生物工程职业技术学院 盐酸阿考替胺膜控型缓释制剂及其制备方法
CN106727350A (zh) * 2016-12-28 2017-05-31 潍坊宇洋药业有限公司 一种林可霉素固体分散体制剂及其制备方法
CN109772234B (zh) 2017-11-14 2024-01-05 中国石油化工股份有限公司 用于丙烯氨氧化反应器的原料气进料系统
EP3749289A4 (fr) * 2018-02-06 2021-11-17 Robert Niichel Produit multiparticulaire comprenant des substances actives pharmaceutiques ou probiotiques
CA3151010A1 (fr) * 2019-09-24 2021-04-01 Arturo J. Angel Formulations liquides de rifaximine
WO2022090490A1 (fr) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Formulations liquides de rifaximine destinées à être utilisées dans le traitement de la drépanocytose
GB202304248D0 (en) * 2023-03-23 2023-05-10 Univ Liverpool Rifapentine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
ES2109377T3 (es) * 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
IT1320176B1 (it) * 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
EP1727520A2 (fr) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Procede de preparation de cocristaux a phase mixte avec des agents actifs
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
ES2389358T5 (es) * 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
CN101502513A (zh) * 2008-09-04 2009-08-12 山东淄博新达制药有限公司 一种利福昔明缓释制剂组合物及其制备方法
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
NZ599944A (en) * 2009-10-27 2015-10-30 Lupin Ltd Solid dispersion of rifaximin

Also Published As

Publication number Publication date
UA110199C2 (en) 2015-12-10
US20140221414A1 (en) 2014-08-07
GEP201706693B (en) 2017-07-10
KR102456997B1 (ko) 2022-10-19
CN113274355B (zh) 2023-05-30
IL219508A0 (en) 2012-06-28
KR20140015140A (ko) 2014-02-06
AU2016213722B2 (en) 2018-05-24
JP2013508451A (ja) 2013-03-07
JP6234412B2 (ja) 2017-11-22
NZ599944A (en) 2015-10-30
TN2012000195A1 (en) 2013-12-12
KR20190000931A (ko) 2019-01-03
PE20121185A1 (es) 2012-09-15
JP2016006117A (ja) 2016-01-14
MX346660B (es) 2017-03-28
RU2012121599A (ru) 2013-12-10
KR20170126513A (ko) 2017-11-17
SG10201501054TA (en) 2015-04-29
AU2016213722A1 (en) 2016-08-25
ES2712080T3 (es) 2019-05-09
IL219508A (en) 2017-04-30
WO2011051971A3 (fr) 2011-09-09
CL2012001080A1 (es) 2012-11-05
MY177151A (en) 2020-09-08
EP2493456B1 (fr) 2018-11-21
CN102665693A (zh) 2012-09-12
WO2011051971A2 (fr) 2011-05-05
CA2778981C (fr) 2019-04-02
US20200375959A1 (en) 2020-12-03
CA2778981A1 (fr) 2011-05-05
ZA201203226B (en) 2012-12-27
CN113274355A (zh) 2021-08-20
MX2012004954A (es) 2012-09-07
AU2010313078A1 (en) 2012-05-24
EP2493456A2 (fr) 2012-09-05
JP6211768B2 (ja) 2017-10-11
KR20210156355A (ko) 2021-12-24
KR20200100215A (ko) 2020-08-25
US20120214833A1 (en) 2012-08-23
KR101972354B1 (ko) 2019-04-25

Similar Documents

Publication Publication Date Title
MA33761B1 (fr) Dispersion solide de rifaximine
MY154909A (en) Novel thiophene derivatives
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
TW200738670A (en) Novel thiophene derivatives
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
ZA200807274B (en) Novel pyridine derivatives
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
MX2010009646A (es) Agentes terapeuticos antivirales.
MY165889A (en) Compositions and methods of using proislet peptides and analogs thereof
TW200626132A (en) Topical nepafenac formulations
MX2010004576A (es) Derivados de pirimidina novedosos.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
UA96449C2 (en) Stable laquinimod preparations
EA201170703A1 (ru) Производные адамантилбензамида
MY145074A (en) Thiazolidin-4-one derivatives
TW200800967A (en) Benzimidazole thiophene compounds
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
TW200942524A (en) Novel aminomethyl benzene derivatives
MA34883B1 (fr) Nouvelle composition pharmaceutique